Rhythm Pharmaceuticals, Inc. beat EPS estimates 56% of the time across 16 reported quarters (9 beats, 7 misses), averaging -0.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.81 | $-0.73 | +9.9% | Beat | |
| Q1 FY26 | $-0.86 | $-0.83 | +3.5% | Beat | |
| Q4 FY25 | $-0.79 | $-0.73 | +7.6% | Beat | Q4 FY25 call |
| Q3 FY25 | $-0.72 | $-0.82 | -13.9% | Miss | |
| Q2 FY25 | $-0.66 | $-0.75 | -13.6% | Miss | Q2 FY25 call |
| Q1 FY25 | $-0.69 | $-0.81 | -17.4% | Miss | |
| Q4 FY24 | $-0.69 | $-0.72 | -4.3% | Miss | |
| Q3 FY24 | $-0.80 | $-0.73 | +8.8% | Beat | |
| Q2 FY24 | $-0.70 | $-0.55 | +21.4% | Beat | |
| Q1 FY24 | $-2.34 | $-2.35 | -0.4% | Miss | |
| Q4 FY23 | $-0.70 | $-0.70 | +0.0% | Beat | |
| Q3 FY23 | $-0.76 | $-0.76 | +0.0% | Beat |
Back to RYTM overview · RYTM holders · RYTM KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.